IP Library › Granted Patent US 12692294
Granted Patent B2
US 12692294 · App. 17/836,425 · Granted Jul 28, 2026

Engineered NRG-1 variants with improved selectivity toward ErbB4 but not against ErbB3

Inventors: Darren L. Bates (Oak Park, CA); Zhi Liu (Shoreline, WA); TaeWeon Lee (Palo Alto, CA); Mark L. Michaels (Encino, CA); Zhulun Wang (Palo Alto, CA)
Assignee: Amgen Inc.
C07K14/485A61P9/10A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12692294
App. No.
17/836,425
Granted
Jul 28, 2026
Kind
B2
Abstract

The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.

Claims (4)

1 . A neuregulin variant is represented by an amino acid sequence of SEQ ID NO: 117 or 126.

2 . The neuregulin variant of claim 1 , further comprising a second amino acid sequence comprising a signal sequence, a half-life extension moiety, or purification tag.

3 . The neuregulin variant of claim 2 , wherein the second amino acid sequence comprises an Fc region or a His Tag.

4 . A pharmaceutical composition comprising the neuregulin variant of any one of claims 1, 2, and 3 , and a pharmaceutically acceptable carrier.